Abstract 2142P
Background
The improvement in cancer survival, allows for higher ICU admission ratios. A pilot program in our center instituted weekly meetings between ICU and Oncology aimed at determining the appropriate level of care for patients admitted in Oncology. Objective: establish which factors predict decision-making regarding the level of care and admission to the ICU and benefit of intensive care.
Methods
Single-center prospective observational study. Recruitment between September-2021 and July-2022. Statistical analysis: descriptive study, multivariate logistic regression for decision of admission in ICU. We performed a second subsequent analysis with the paired propensity score matching technique. Survival analysis: Kaplan-Meier (KM) curves and log-Rank test. Significance level: p ≤ 0.05.
Results
411 patients. 60.3% male; median age: 64 years. Most prevalent tumor: lung (26.3%). Stage IV: 72.5%. The most common reason for admission in Oncology: infectious pathology (33.8%). 54.7% were considered ICU candidates, while only 17 patients (4.1%) finally required intensive care. In a multivariate logistic regression model, ECOG 0-1 (OR 2.7; IC95%: 1.6-4.5), absence of peritoneal carcinomatosis (OR 4.5; IC95%: 2.0-9.9), and intentionality of treatment (adjuvant, neoadjuvant or first-line) (OR 5.4; IC 95%: 3.1-9.5) predicted decision of admission to the ICU. Age > 65 years (OR 0.35; IC 95%: 0.2-0.6) and poor symptom control as cause of admission in Oncology (OR 0.16; 95%: 0.03-0.93) were negative factors for ICU admission. By means of paired propensity analysis (Nearest-neighbor model), the sample was reduced to 172 patients and there was only statistical significance in the univariate analysis for intentionality of treatment and for treatment with immunotherapy (IT). After a median follow-up of 4 months, median survival was significantly different (p< 0.05) for patients who were not ICU candidates (2.5 months), patients who were admitted to the ICU (10 months) and patients who were ICU candidates but did not require admission (12.5 months).
Conclusions
Multidisciplinary decision-making may contribute to individualize the level of intensive care for Oncology patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
F. Ayala de la Pena
Funding
Has not received any funding.
Disclosure
M. Sanchez Canovas: Financial Interests, Advisory Board: Leo Pharma, Sanofi, Lundbeck, Angelini. All other authors have declared no conflicts of interest.
Resources from the same session
2247P - Expression of PD-L1 on circulating epithelial tumor cells (CETCs) in men with primary non-metastatic prostate cancer
Presenter: Dorothea Schott
Session: Poster session 07
2248P - Capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer (PANDORA trial): Molecular profiling and translational results
Presenter: Stefano Tamberi
Session: Poster session 07
2249P - Mitigation of tumor microenvironment-mediated immunosuppression using a PD1-41BB switch protein with optimal affinity tcrs for first-in-class, 3rd generation TCR-T therapies
Presenter: Kirsty Crame
Session: Poster session 07
2250P - Exploring tumor microenvironment in lung cancer through patient-derived 3D models
Presenter: NORA JUCIUTE
Session: Poster session 07
2251P - The genomic landscape of radiotherapy-induced breast angiosarcoma: An alleanza contro il cancro (ACC) initiative for an unmet need in rare tumors
Presenter: Lorenzo Ferrando
Session: Poster session 07